Combining Atezolizumab and Bevacizumab to Control Rare Tumors
Type: Pleural/Peritoneal Mesothelioma
Researchers are hoping that by combing the drugs atezolizumab (Tecentriq) and bevacizumab (Avastin), that they will be able to help control rare solid tumors, including mesothelioma.
Each mesothelioma patient will receive both atezolizumab and bevacizumab by vein for 3 weeks. On day 1 of each 21-day cycle, each participant will receive the drug atezolizumab prior to receiving the drug bevacizumab.
Drugs in This Trial
Atezolizumab – works by blocking PD-L1, a protein in some cancer cells that suppresses the immune system. By blocking PD-L1, atezolizumab allows the immune system to fight against the cancer and helps slow down tumor growth. This drug is usually used to combat cancer that is in the lining of the bladder and in other areas of the urinary tract.
Bevacizumab – works by stopping the formation of blood vessels that fuel tumors with oxygen and nutrients. By doing this, it not only slows down the growth of tumors, but it prohibits them from spreading. This drug is often used in combination with chemotherapy and has been used to treat lung cancer, colon and rectum cancer, breast cancer, renal cell cancer, and brain tumors.
Get Help Enrolling in This Trial
Reasons to get involved in this trial include:
- Receiving proven life-extending treatment
- Getting treatment at the top cancer centers in the country
- Eligible to stay in the study as long as trial doctor approves
Side Effects of Atezolizumab & Bevacizumab
A participant in this study will be able to stay in the clinical trial for as long as the trial’s doctor deems it is safe for them. The doctor’s decision will be based off of how a participant responds to treatment and what kind of side effects they may have.
In previous trials, some side effects that have been associated with atezolizumab are:
- Hair loss
- Weight gain or weight loss
- Nausea or vomiting
In previous trials, some side effects that have been associated with bevacizumab are:
- Weight loss
- Dry mouth
Every 3 months a participant will be contacted by the study staff to be checked up on. If a participant finds themselves experiencing any severe reactions to the treatment, they will no longer be able to participate in the study.
Getting Involved in This Study
A few requirements a participant must have for this clinical trial are:
- Metastatic or locally recurrent disease that isn’t operable
- Refractory to platinum and pemetrexed system therapy
- ECOG Performance Status of 0 or 1
A few criteria that would make a participant ineligible for this clinical trial are:
- A severe infection 4 weeks prior to starting the study
- Been hospitalized prior to entering the trial due to complications from an infection, bacteremia, or severe pneumonia
- Had other malignancies in the last 5 years, other than their disease that is being studied
This study is happening at the University of Texas MD Anderson Cancer Center. This cancer center is located in Houston, Texas.
Head of this investigation is Dr. Daniel M. Halperin. Dr. Halperin is a medical oncologist and clinical investigator that is focused on creating treatments for patients with neuroendocrine tumors and gastrointestinal cancers.
This clinical trial is currently recruiting participants. If you have any questions about this trial or about your treatment options, please feel free to request our free mesothelioma guide or you can contact us directly with your medical concerns.